Kennedy Capital Management, Inc. Fate Therapeutics Inc Transaction History

Kennedy Capital Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $15,254 - $26,143	-725 Reduced 0.69%	104,881 $2.35 Million
Q2 2022 Aug 10, 2022	SELL	$17.78 - $42.39 $21,229 - $50,613	-1,194 Reduced 1.12%	105,606 $2.62 Million
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $25,160 - $51,117	848 Added 0.8%	106,800 $4.14 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $1.01 Million - $1.36 Million	-21,158 Reduced 16.65%	105,952 $6.2 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $982,933 - $1.59 Million	16,584 Added 15.0%	127,110 $7.53 Million
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $7.43 Million - $10.2 Million	110,526 New	110,526 $9.59 Million
Q2 2020 Aug 14, 2020	SELL	$20.21 - $35.23 $1.52 Million - $2.65 Million	-75,200 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$17.28 - $31.88 $1.3 Million - $2.4 Million	75,200 New	75,200 $1.67 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.